Evidence map›Paper›PMID 29411539›Full record

ArticleMolecular genetics & genomic medicine2018

Association between glutathione peroxidase 1 codon 198 variant and the occurrence of breast cancer in Rwanda.

Thierry Habyarimana, Youssef Bakri, Pacifique Mugenzi, Jean Baptiste Mazarati, Mohammed Attaleb, Mohammed El Mzibri

Open access · goldAbstract read
In one paragraph

Article in Molecular genetics & genomic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. The Journal of international medical research · 2020
    Trial
  2. Review
  3. Clinicopathological Characteristics and Mutational Landscape ofCurrent issues in molecular biology · 2023
    Article
  4. TheReports of biochemistry & molecular biology · 2023
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Thierry HabyarimanaBiology and Medical Research Unit, Centre National de l'Energie, des Sciences et des Techniques Nucléaires (CNESTEN), Rabat, Morocco.ORCID 0000-0001-5488-5578
Youssef BakriBiology of Human Pathologies Laboratory (BioPatH), Faculty of Science & Human Pathologies Center (GenoPatH), Mohammed V University, Rabat, Morocco.
Pacifique MugenziRwanda Military Hospital (RMH), Kigali, Rwanda.
Jean Baptiste MazaratiBiomedical Services Department, Rwanda Biomedical Center (RBC-BIOS), Kigali, Rwanda.
Mohammed AttalebBiology and Medical Research Unit, Centre National de l'Energie, des Sciences et des Techniques Nucléaires (CNESTEN), Rabat, Morocco.
Mohammed El MzibriBiology and Medical Research Unit, Centre National de l'Energie, des Sciences et des Techniques Nucléaires (CNESTEN), Rabat, Morocco.
Mohammed V University · MANational Centre for Nuclear Energy, Science and Technology · MACentre Hospitalier Universitaire de Kigali · RWRwanda Biomedical Center · RW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlutathione peroxidase 1 gene (GPX1) is one of the antioxidant enzyme that remove the reactive oxygen species in a continuous process. Since the identification of a well-characterized functional polymorphism named p.Pro198Leu (rs1050450 C>T) in GPX1 gene, abundant studies have evaluated the association between p.Pro198Leu polymorphism and tumor risk in diverse population. But, the available results related to breast cancer are conflicting and absent in Africa. The present case-control study was planned to assess the presence of GPX1 Pro198Leu polymorphism in Rwanda population to determine whether it is associated with the risk of developing breast cancer.

methodsGenomic DNA from peripheral blood leukocytes of 41 patients with breast cancer and 42 healthy controls were enrolled and genotyped GPX1 Pro198Leu polymorphism by PCR amplification and DNA sequencing.

resultsNo significant difference in the frequencies of Pro/Pro (49%) and Pro/Leu (51%) genotypes in cancer cases and in controls (50% each) were found. The allelic frequencies of Pro and Leu were 74% versus 26% and 75% versus 25% in breast cancer cases and controls respectively. No association was observed in allele frequencies of Pro and Leu, and familial history. Only an overall association of GPX1 Pro198Leu with grade of cancer (Pro/Leu vs. Pro/Pro: p = .0200) was detected.

conclusionThe result of this study suggested that GPX1 Pro198Leu polymorphism could not be a risk factor for breast cancer in Rwanda. However, large-scale studies on the effect of this polymorphism on the factors disturbing the redox homeostasis are needed for conclusive understanding.

Indexed as

AdultAllelesBase SequenceBreast NeoplasmsBreast Neoplasms, MaleCase-Control StudiesCodonFemaleGene FrequencyGenetic Predisposition to DiseaseGenotypeGlutathione PeroxidaseGlutathione Peroxidase GPX1HumansMaleRisk FactorsCodonGlutathione PeroxidaseGlutathione Peroxidase GPX1GPX1 protein, humanbreast cancergene polymorphismGPX1reactive oxygen speciesRwanda

Identifiers

PMID29411539
PMCPMC5902397
OpenAlexW2793310329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.